Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

1987 • 44,619 citations

Reporting results of cancer treatment

1981 • 7,916 citations

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 • 4,805 citations

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

2002 • 3,803 citations

Cancer Statistics, 2003

2003 • 3,302 citations

Cancer—Principles & Practice of Oncology

1983 • 1,403 citations

Small-cell lung cancer

2011 • 1,170 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594

2001 • 259 citations

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

2001 • 236 citations

Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.

1989 • 230 citations

Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation

1987 • 218 citations

EPIDEMIOLOGY OF LUNG CANCER

2000 • 117 citations

Lung cancer: A review

2002 • 116 citations

New Chemotherapy Agents for Small Cell Lung Cancer

2000 • 89 citations

Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

1994 • 88 citations

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

1997 • 63 citations

Combined Modality Treatment of Small Cell Carcinoma of the Lung

1981 • 61 citations

Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.

1990 • 57 citations

Management of small cell lung cancer

2002 • 42 citations

Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy.

1994 • 42 citations

O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC)

2003 • 37 citations

Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.

1986 • 36 citations

Initial therapy with cisplatin plus VP-16 in small-cell lung cancer.

1986 • 35 citations

Single agent oral topotecan (OT) as first-line treatment for patients (pts) with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard therapy: A phase II study

2000 • 33 citations

Retrospective Analysis of the Treatment of Patients with Small Cell Lung Cancer Showing Poor Performance Status

1996 • 17 citations

Comparison of Survival of Patients With Lung Cancer Between Elderly (≧70) and Younger (70>) Age Groups

1986 • 14 citations

Resolution of superior vena cava obstruction in small cell lung cancer patients treated with chemotherapy.

1995 • 8 citations

Deleted Work

1955 • 0 citations